Chengdu Shengnuo Biopharm Co Ltd

About Chengdu Shengnuo Biopharm Co Ltd

Chengdu Shengnuo is one of the leading peptide manufacturers in China. There are 5 US-DMF of Peptide APIs:  Liraglutide, Bivalirudin, Eptifibatide, Icatibant and Octreotide. The below US-DMFs will be submitted soon: Linaclotide, Degarelix,  Teriparatide,Ziconotide,Exenatide and Ganirelix  soon. Shengnuo also have a few Chinese GMP APIs: Atosiban,Carbetocin, Octreotide, Enfuvirtide,Thymalfasin, Somatostatin, Thymopentin and Levosimendan.Chengdu Shengnuo Biopharm Co Ltd is a subsidiary of Chengdu Shengnuo Tech Development Co Ltd and was founded in October 2004. With 50 key technologies for large-scale production of domestic and foreign peptide drugs, we are a leading manufacturer of peptides by solid-phase chemistry. In addition, our team has the ability to perform product development, technology transfer, technical services and large-scale multi-kilogram single batch production capacities. As an industry leader in the domestic solid-phase peptide market, we have recently received approval as a registered US FDA manufacturing facility with zero...

  • CN
  • 2015
    On CPHI since
Contact info

Products from Chengdu Shengnuo Biopharm Co Ltd (3)

  • Bivalirudin

    Product Bivalirudin

     Use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty .Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the ...
  • Icatibant

    Product Icatibant

    is a synthetic peptidomimetic drug consisting of ten amino acids, and acts as an effective and specific antagonist of bradykinin B2 receptors. It has been approved in the EU for use in hereditary angioedema, and is under investigation for a number of other conditions in which bradykinin is thought to play a s...
  • Liraglutide

    Product Liraglutide

    Diabetes mellitus, 
    Liraglutide is a once-daily GLP-1 derivative for the treatment of type 2 diabetesLabel,2. The prolonged action of liraglutide is achieved by attaching a fatty acid molecule at position 26 of the GLP-1 molecule, enabling it to bind reversibly to albumin within the subcutaneous t...